These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 28178682)

  • 1. Comprehensive analysis of PD-L1 expression in glioblastoma multiforme.
    Heiland DH; Haaker G; Delev D; Mercas B; Masalha W; Heynckes S; Gäbelein A; Pfeifer D; Carro MS; Weyerbrock A; Prinz M; Schnell O
    Oncotarget; 2017 Jun; 8(26):42214-42225. PubMed ID: 28178682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme.
    Heynckes S; Daka K; Franco P; Gaebelein A; Frenking JH; Doria-Medina R; Mader I; Delev D; Schnell O; Heiland DH
    BMC Cancer; 2019 Feb; 19(1):117. PubMed ID: 30709339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies.
    Garber ST; Hashimoto Y; Weathers SP; Xiu J; Gatalica Z; Verhaak RG; Zhou S; Fuller GN; Khasraw M; de Groot J; Reddy SK; Spetzler D; Heimberger AB
    Neuro Oncol; 2016 Oct; 18(10):1357-66. PubMed ID: 27370400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Programmed Death Ligand 1 Is a Negative Prognostic Marker in Recurrent Isocitrate Dehydrogenase-Wildtype Glioblastoma.
    Pratt D; Dominah G; Lobel G; Obungu A; Lynes J; Sanchez V; Adamstein N; Wang X; Edwards NA; Wu T; Maric D; Giles AJ; Gilbert MR; Quezado M; Nduom EK
    Neurosurgery; 2019 Aug; 85(2):280-289. PubMed ID: 30011045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles.
    Ricklefs FL; Alayo Q; Krenzlin H; Mahmoud AB; Speranza MC; Nakashima H; Hayes JL; Lee K; Balaj L; Passaro C; Rooj AK; Krasemann S; Carter BS; Chen CC; Steed T; Treiber J; Rodig S; Yang K; Nakano I; Lee H; Weissleder R; Breakefield XO; Godlewski J; Westphal M; Lamszus K; Freeman GJ; Bronisz A; Lawler SE; Chiocca EA
    Sci Adv; 2018 Mar; 4(3):eaar2766. PubMed ID: 29532035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of PD-1 positive cells on initial and secondary resected tumor specimens of newly diagnosed glioblastoma and its implications on patient outcome.
    Miyazaki T; Ishikawa E; Matsuda M; Akutsu H; Osuka S; Sakamoto N; Takano S; Yamamoto T; Tsuboi K; Matsumura A
    J Neurooncol; 2017 Jun; 133(2):277-285. PubMed ID: 28447277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current advances in PD-1/PD-L1 axis-related tumour-infiltrating immune cells and therapeutic regimens in glioblastoma.
    Shu C; Li Q
    Crit Rev Oncol Hematol; 2020 Jul; 151():102965. PubMed ID: 32442903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the PD-1/PD-L1 pathway in glioblastoma multiforme: Preclinical evidence and clinical interventions.
    Maghrouni A; Givari M; Jalili-Nik M; Mollazadeh H; Bibak B; Sadeghi MM; Afshari AR; Johnston TP; Sahebkar A
    Int Immunopharmacol; 2021 Apr; 93():107403. PubMed ID: 33581502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma.
    Maxwell R; Jackson CM; Lim M
    Curr Treat Options Oncol; 2017 Aug; 18(8):51. PubMed ID: 28785997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pan-cancer analysis of copy number changes in programmed death-ligand 1 (PD-L1, CD274) - associations with gene expression, mutational load, and survival.
    Budczies J; Bockmayr M; Denkert C; Klauschen F; Gröschel S; Darb-Esfahani S; Pfarr N; Leichsenring J; Onozato ML; Lennerz JK; Dietel M; Fröhling S; Schirmacher P; Iafrate AJ; Weichert W; Stenzinger A
    Genes Chromosomes Cancer; 2016 Aug; 55(8):626-39. PubMed ID: 27106868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of PD-L1 expression and T cell infiltration in different molecular subgroups of diffuse midline gliomas.
    Jha P; Manjunath N; Singh J; Mani K; Garg A; Kaur K; Sharma MC; Raheja A; Suri A; Sarkar C; Suri V
    Neuropathology; 2019 Dec; 39(6):413-424. PubMed ID: 31625205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MET overexpression contributes to STAT4-PD-L1 signaling activation associated with tumor-associated, macrophages-mediated immunosuppression in primary glioblastomas.
    Wang QW; Sun LH; Zhang Y; Wang Z; Zhao Z; Wang ZL; Wang KY; Li GZ; Xu JB; Ren CY; Ma WP; Wang HJ; Li SW; Zhu YJ; Jiang T; Bao ZS
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34667077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppressing PD-L1 Expression via AURKA Kinase Inhibition Enhances Natural Killer Cell-Mediated Cytotoxicity against Glioblastoma.
    Nguyen TTT; Gao Q; Mun JY; Zhu Z; Shu C; Naim A; Rogava M; Izar B; Westhoff MA; Karpel-Massler G; Siegelin MD
    Cells; 2024 Jul; 13(13):. PubMed ID: 38995006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-L1 confers glioblastoma multiforme malignancy via Ras binding and Ras/Erk/EMT activation.
    Qiu XY; Hu DX; Chen WQ; Chen RQ; Qian SR; Li CY; Li YJ; Xiong XX; Liu D; Pan F; Yu SB; Chen XQ
    Biochim Biophys Acta Mol Basis Dis; 2018 May; 1864(5 Pt A):1754-1769. PubMed ID: 29510196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-L1-Mediated Immunosuppression in Glioblastoma Is Associated With the Infiltration and M2-Polarization of Tumor-Associated Macrophages.
    Zhu Z; Zhang H; Chen B; Liu X; Zhang S; Zong Z; Gao M
    Front Immunol; 2020; 11():588552. PubMed ID: 33329573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-L1 expression and prognostic impact in glioblastoma.
    Nduom EK; Wei J; Yaghi NK; Huang N; Kong LY; Gabrusiewicz K; Ling X; Zhou S; Ivan C; Chen JQ; Burks JK; Fuller GN; Calin GA; Conrad CA; Creasy C; Ritthipichai K; Radvanyi L; Heimberger AB
    Neuro Oncol; 2016 Feb; 18(2):195-205. PubMed ID: 26323609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma PD-L1 as a biomarker in the clinical management of glioblastoma multiforme-a retrospective cohort study.
    Masood AB; Batool S; Bhatti SN; Ali A; Valko M; Jomova K; Kuca K
    Front Immunol; 2023; 14():1202098. PubMed ID: 37529045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression differences of programmed death ligand 1 in de-novo and recurrent glioblastoma multiforme.
    Heynckes S; Gaebelein A; Haaker G; Grauvogel J; Franco P; Mader I; Carro MS; Prinz M; Delev D; Schnell O; Heiland DH
    Oncotarget; 2017 Sep; 8(43):74170-74177. PubMed ID: 29088776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrative Diffusion-Weighted Imaging and Radiogenomic Network Analysis of Glioblastoma multiforme.
    Heiland DH; Simon-Gabriel CP; Demerath T; Haaker G; Pfeifer D; Kellner E; Kiselev VG; Staszewski O; Urbach H; Weyerbrock A; Mader I
    Sci Rep; 2017 Mar; 7():43523. PubMed ID: 28266556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequency of mismatch repair protein deficiency and PD-L1 in high-grade gliomas in adolescents and young adults (AYA).
    Almuhaisen G; Alhalaseh Y; Mansour R; Abu-Shanab A; Al-Ghnimat S; Al-Hussaini M
    Brain Tumor Pathol; 2021 Jan; 38(1):14-22. PubMed ID: 32897465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.